Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2023-11-14 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2023年第五次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 fifth extraordinary general meeting of shareholders of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the voting outcomes and decisions made by shareholders rather than presenting financial data or management discussion. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and is a full announcement of voting results, not a mere notice or report publication announcement. Therefore, the correct classification is DVA with high confidence.
2023-11-14 Chinese
关于媒体及投资者调研情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about a media and investor research session held by the company, including Q&A on business strategy, product details, recent financial performance (referencing the recently published third quarter report), and future plans. It includes specific financial figures for the first three quarters and discusses business segments and product approvals. However, it is not the actual quarterly report itself but a summary and discussion referencing the third quarter report. The document length is 3467 characters, which is relatively short and more consistent with an announcement or summary rather than a full interim/quarterly report containing full financial statements and detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it does not contain the full financial statements or substantive financial data of an Interim/Quarterly Report (IR), but rather a company announcement about investor relations and business updates referencing the quarterly results.
2023-11-05 Chinese
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System'. It details the company's internal policies and procedures for managing and using funds raised through securities issuance. The content includes rules on the storage, usage, supervision, and changes in the use of raised funds, as well as the responsibilities of the board and other parties. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. Instead, it is a detailed governance document related to capital management practices. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP), as it provides an update on the company's fundraising capital management policies and procedures.
2023-10-25 Chinese
董事会提名委员会议事规则
Governance Information Classification · 95% confidence The document is titled '董事会提名委员会议事规则' which translates to 'Board Nomination Committee Meeting Rules'. It details the rules, composition, responsibilities, meeting procedures, and confidentiality obligations of the board nomination committee. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, and no earnings information. The document is a governance-related internal rules document about the board nomination committee. It is not a report or announcement of financial results or corporate actions. Therefore, the document fits best under Governance Information (CGR). The document length is 4396 characters, which is sufficient for a detailed governance document. Confidence is high due to the clear content focus on governance rules and board committee procedures.
2023-10-25 Chinese
独立董事专门会议制度
Governance Information Classification · 95% confidence The document is a detailed description of the "Independent Directors Special Meeting System" of Shanxi Jinbo Biopharmaceutical Co., Ltd. It outlines governance procedures, meeting protocols, voting rules, and the roles and responsibilities of independent directors. The content focuses on corporate governance structure and internal rules rather than financial data, earnings, or shareholder voting results. There is no indication that this is a report of financial results, an announcement of voting outcomes, or a regulatory filing of a different nature. The document is not a presentation or a call transcript. It is a governance-related document detailing internal rules and procedures for independent directors' meetings, which fits the definition of Governance Information (CGR). The document length is 2570 characters, which is sufficient for a substantive governance report rather than a brief announcement. Therefore, the appropriate classification is CGR with high confidence.
2023-10-25 Chinese
承诺管理制度
Governance Information Classification · 95% confidence The document is titled '承诺管理制度' (Commitment Management System) and details the company's internal policies regarding commitments made by the company, controlling shareholders, and related parties. It includes sections on the nature of commitments, disclosure requirements, procedures for changes or waivers, and governance around these commitments. There is no financial data, no mention of financial results, no voting results, no executive changes, no legal proceedings, no capital changes, and no regulatory certifications. The document is a policy or governance-related disclosure about commitment management. It is not a report or announcement of a report, nor a certification. It fits best under Governance Information (CGR) as it details internal rules and governance practices related to commitments and disclosures.
2023-10-25 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.